Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Aberrant expression of maspin in idiopathic inflammatory bowel disease is associated with disease activity and neoplastic transformation.

Cao D, Wilentz RE, Abbruzzese JL, Ho L, Maitra A.

Int J Gastrointest Cancer. 2005;36(1):39-46.

PMID:
16227634
2.
3.

HLA-G upregulation in pre-malignant and malignant lesions of the gastrointestinal tract.

Hansel DE, Rahman A, Wilentz RE, Shih IeM, McMaster MT, Yeo CJ, Maitra A.

Int J Gastrointest Cancer. 2005;35(1):15-23.

PMID:
15722570
4.

RPL38, FOSL1, and UPP1 are predominantly expressed in the pancreatic ductal epithelium.

Sahin F, Qiu W, Wilentz RE, Iacobuzio-Donahue CA, Grosmark A, Su GH.

Pancreas. 2005 Mar;30(2):158-67.

5.

Immunohistochemistry and in situ hybridization in pancreatic neoplasia.

Wilentz RE, Rahman A, Argani P, Iacobuzio-Donahue C.

Methods Mol Med. 2005;103:67-88. Review.

PMID:
15542898
6.

Identification and analysis of precursors to invasive pancreatic cancer.

Hruban RH, Wilentz RE, Maitra A.

Methods Mol Med. 2005;103:1-13. Review.

PMID:
15542896
7.

Systemic BCNU enhances the efficacy of local delivery of a topoisomerase I inhibitor against malignant glioma.

Storm PB, Renard VM, Moriarity JL, Tyler B, Wilentz RE, Brem H, Weingart JD.

Cancer Chemother Pharmacol. 2004 Oct;54(4):361-7. Epub 2004 Jun 10.

PMID:
15197484
8.

Expression of neuropilin-1 in high-grade dysplasia, invasive cancer, and metastases of the human gastrointestinal tract.

Hansel DE, Wilentz RE, Yeo CJ, Schulick RD, Montgomery E, Maitra A.

Am J Surg Pathol. 2004 Mar;28(3):347-56.

PMID:
15104297
9.

p16 Inactivation in pancreatic intraepithelial neoplasias (PanINs) arising in patients with chronic pancreatitis.

Rosty C, Geradts J, Sato N, Wilentz RE, Roberts H, Sohn T, Cameron JL, Yeo CJ, Hruban RH, Goggins M.

Am J Surg Pathol. 2003 Dec;27(12):1495-501.

PMID:
14657708
10.

Novel markers of pancreatic adenocarcinoma in fine-needle aspiration: mesothelin and prostate stem cell antigen labeling increases accuracy in cytologically borderline cases.

McCarthy DM, Maitra A, Argani P, Rader AE, Faigel DO, Van Heek NT, Hruban RH, Wilentz RE.

Appl Immunohistochem Mol Morphol. 2003 Sep;11(3):238-43.

PMID:
12966350
11.

Analysis of anaphase figures in routine histologic sections distinguishes chromosomally unstable from chromosomally stable malignancies.

Montgomery E, Wilentz RE, Argani P, Fisher C, Hruban RH, Kern SE, Lengauer C.

Cancer Biol Ther. 2003 May-Jun;2(3):248-52.

PMID:
12878857
12.

Atheroembolism in cardiac surgery.

Doty JR, Wilentz RE, Salazar JD, Hruban RH, Cameron DE.

Ann Thorac Surg. 2003 Apr;75(4):1221-6.

PMID:
12683567
13.

Role of the DPC4 tumor suppressor gene in adenocarcinoma of the ampulla of Vater: analysis of 140 cases.

McCarthy DM, Hruban RH, Argani P, Howe JR, Conlon KC, Brennan MF, Zahurak M, Wilentz RE, Cameron JL, Yeo CJ, Kern SE, Klimstra DS.

Mod Pathol. 2003 Mar;16(3):272-8.

14.

Premalignant conditions of the pancreas.

Hall Pde L, Wilentz RE, de Klerk W, Bornman PP.

Pathology. 2002 Dec;34(6):504-17. Review.

PMID:
12555988
15.

Pancreaticoduodenectomy (Whipple resections) in patients without malignancy: are they all 'chronic pancreatitis'?

Abraham SC, Wilentz RE, Yeo CJ, Sohn TA, Cameron JL, Boitnott JK, Hruban RH.

Am J Surg Pathol. 2003 Jan;27(1):110-20.

PMID:
12502933
16.

Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia.

van Heek NT, Meeker AK, Kern SE, Yeo CJ, Lillemoe KD, Cameron JL, Offerhaus GJ, Hicks JL, Wilentz RE, Goggins MG, De Marzo AM, Hruban RH, Maitra A.

Am J Pathol. 2002 Nov;161(5):1541-7.

17.

Pancreatic cancer.

Yeo TP, Hruban RH, Leach SD, Wilentz RE, Sohn TA, Kern SE, Iacobuzio-Donahue CA, Maitra A, Goggins M, Canto MI, Abrams RA, Laheru D, Jaffee EM, Hidalgo M, Yeo CJ.

Curr Probl Cancer. 2002 Jul-Aug;26(4):176-275. Review. No abstract available.

PMID:
12399802
18.

The dichotomy in the preinvasive neoplasia to invasive carcinoma sequence in the pancreas: differential expression of MUC1 and MUC2 supports the existence of two separate pathways of carcinogenesis.

Adsay NV, Merati K, Andea A, Sarkar F, Hruban RH, Wilentz RE, Goggins M, Iocobuzio-Donahue C, Longnecker DS, Klimstra DS.

Mod Pathol. 2002 Oct;15(10):1087-95.

19.

Smad4 overexpression in hepatocellular carcinoma is strongly associated with transforming growth factor beta II receptor immunolabeling.

Torbenson M, Marinopoulos S, Dang DT, Choti M, Ashfaq R, Maitra A, Boitnott J, Wilentz RE.

Hum Pathol. 2002 Sep;33(9):871-6.

PMID:
12378510
20.

Hepatocellular carcinomas show abnormal expression of fibronectin protein.

Torbenson M, Wang J, Choti M, Ashfaq R, Maitra A, Wilentz RE, Boitnott J.

Mod Pathol. 2002 Aug;15(8):826-30.

21.

Cyclooxygenase 2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia: an immunohistochemical analysis with automated cellular imaging.

Maitra A, Ashfaq R, Gunn CR, Rahman A, Yeo CJ, Sohn TA, Cameron JL, Hruban RH, Wilentz RE.

Am J Clin Pathol. 2002 Aug;118(2):194-201.

PMID:
12162677
22.

Immunohistochemical validation of a novel epithelial and a novel stromal marker of pancreatic ductal adenocarcinoma identified by global expression microarrays: sea urchin fascin homolog and heat shock protein 47.

Maitra A, Iacobuzio-Donahue C, Rahman A, Sohn TA, Argani P, Meyer R, Yeo CJ, Cameron JL, Goggins M, Kern SE, Ashfaq R, Hruban RH, Wilentz RE.

Am J Clin Pathol. 2002 Jul;118(1):52-9.

PMID:
12109856
23.

MUC4 expression increases progressively in pancreatic intraepithelial neoplasia.

Swartz MJ, Batra SK, Varshney GC, Hollingsworth MA, Yeo CJ, Cameron JL, Wilentz RE, Hruban RH, Argani P.

Am J Clin Pathol. 2002 May;117(5):791-6.

PMID:
12090430
24.

K-ras, p53, and DPC4 (MAD4) alterations in fine-needle aspirates of the pancreas: a molecular panel correlates with and supplements cytologic diagnosis.

van Heek T, Rader AE, Offerhaus GJ, McCarthy DM, Goggins M, Hruban RH, Wilentz RE.

Am J Clin Pathol. 2002 May;117(5):755-65.

PMID:
12090425
25.

Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma.

Fukushima N, Sato N, Ueki T, Rosty C, Walter KM, Wilentz RE, Yeo CJ, Hruban RH, Goggins M.

Am J Pathol. 2002 May;160(5):1573-81.

27.

Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations.

Abraham SC, Klimstra DS, Wilentz RE, Yeo CJ, Conlon K, Brennan M, Cameron JL, Wu TT, Hruban RH.

Am J Pathol. 2002 Apr;160(4):1361-9.

28.

The latest in pancreatic cancer research: Lustgarten Foundation awardees present their findings.

Wilentz RE.

Int J Pancreatol. 2001;29(2):123-5. No abstract available.

PMID:
11876250
29.

Immunohistochemical labeling for the Dpc4 gene product is a specific marker for adenocarcinoma in biopsy specimens of the pancreas and bile duct.

Tascilar M, Offerhaus GJ, Altink R, Argani P, Sohn TA, Yeo CJ, Cameron JL, Goggins M, Hruban RH, Wilentz RE.

Am J Clin Pathol. 2001 Dec;116(6):831-7.

PMID:
11764071
30.

Almost all infiltrating colloid carcinomas of the pancreas and periampullary region arise from in situ papillary neoplasms: a study of 39 cases.

Seidel G, Zahurak M, Iacobuzio-Donahue C, Sohn TA, Adsay NV, Yeo CJ, Lillemoe KD, Cameron JL, Hruban RH, Wilentz RE.

Am J Surg Pathol. 2002 Jan;26(1):56-63.

PMID:
11756769
31.

The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma.

Tascilar M, Skinner HG, Rosty C, Sohn T, Wilentz RE, Offerhaus GJ, Adsay V, Abrams RA, Cameron JL, Kern SE, Yeo CJ, Hruban RH, Goggins M.

Clin Cancer Res. 2001 Dec;7(12):4115-21.

32.

Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE).

Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, Murugesan SR, Leach SD, Jaffee E, Yeo CJ, Cameron JL, Kern SE, Hruban RH.

Clin Cancer Res. 2001 Dec;7(12):3862-8.

34.

Molecular pathology of pancreatic cancer.

Hruban RH, Iacobuzio-Donahue C, Wilentz RE, Goggins M, Kern SE.

Cancer J. 2001 Jul-Aug;7(4):251-8. Review.

PMID:
11561601
35.

Loss of Smad4 function in pancreatic tumors: C-terminal truncation leads to decreased stability.

Maurice D, Pierreux CE, Howell M, Wilentz RE, Owen MJ, Hill CS.

J Biol Chem. 2001 Nov 16;276(46):43175-81. Epub 2001 Sep 11.

36.

Myofibroblastoma of the male breast: imaging appearance and ultrasound-guided core biopsy diagnosis.

Dockery WD, Singh HR, Wilentz RE.

Breast J. 2001 May-Jun;7(3):192-4.

PMID:
11469935
37.

Pancreatic intraepithelial neoplasia and infiltrating adenocarcinoma: analysis of progression and recurrence by DPC4 immunohistochemical labeling.

McCarthy DM, Brat DJ, Wilentz RE, Yeo CJ, Cameron JL, Kern SE, Hruban RH.

Hum Pathol. 2001 Jun;32(6):638-42.

PMID:
11431719
38.

Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma.

Argani P, Rosty C, Reiter RE, Wilentz RE, Murugesan SR, Leach SD, Ryu B, Skinner HG, Goggins M, Jaffee EM, Yeo CJ, Cameron JL, Kern SE, Hruban RH.

Cancer Res. 2001 Jun 1;61(11):4320-4.

39.

Loss of heterozygosity or intragenic mutation, which comes first?

Wilentz RE, Argani P, Hruban RH.

Am J Pathol. 2001 May;158(5):1561-3. No abstract available.

40.

Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer.

Tersmette AC, Petersen GM, Offerhaus GJ, Falatko FC, Brune KA, Goggins M, Rozenblum E, Wilentz RE, Yeo CJ, Cameron JL, Kern SE, Hruban RH.

Clin Cancer Res. 2001 Mar;7(3):738-44.

41.

Differing rates of loss of DPC4 expression and of p53 overexpression among carcinomas of the proximal and distal bile ducts.

Argani P, Shaukat A, Kaushal M, Wilentz RE, Su GH, Sohn TA, Yeo CJ, Cameron JL, Kern SE, Hruban RH.

Cancer. 2001 Apr 1;91(7):1332-41.

PMID:
11283934
42.

Dpc4 protein in mucinous cystic neoplasms of the pancreas: frequent loss of expression in invasive carcinomas suggests a role in genetic progression.

Iacobuzio-Donahue CA, Wilentz RE, Argani P, Yeo CJ, Cameron JL, Kern SE, Hruban RH.

Am J Surg Pathol. 2000 Nov;24(11):1544-8.

PMID:
11075857
44.

Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas.

Iacobuzio-Donahue CA, Klimstra DS, Adsay NV, Wilentz RE, Argani P, Sohn TA, Yeo CJ, Cameron JL, Kern SE, Hruban RH.

Am J Pathol. 2000 Sep;157(3):755-61.

45.

Genetic progression in the pancreatic ducts.

Hruban RH, Wilentz RE, Kern SE.

Am J Pathol. 2000 Jun;156(6):1821-5. Review. No abstract available.

46.

Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: A newly described and characterized entity.

Wilentz RE, Goggins M, Redston M, Marcus VA, Adsay NV, Sohn TA, Kadkol SS, Yeo CJ, Choti M, Zahurak M, Johnson K, Tascilar M, Offerhaus GJ, Hruban RH, Kern SE.

Am J Pathol. 2000 May;156(5):1641-51.

47.

Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression.

Wilentz RE, Iacobuzio-Donahue CA, Argani P, McCarthy DM, Parsons JL, Yeo CJ, Kern SE, Hruban RH.

Cancer Res. 2000 Apr 1;60(7):2002-6.

48.

Mucinous cystic neoplasms of the pancreas.

Wilentz RE, Albores-Saavedra J, Hruban RH.

Semin Diagn Pathol. 2000 Feb;17(1):31-42. Review.

PMID:
10721805
49.

Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation.

Wilentz RE, Su GH, Dai JL, Sparks AB, Argani P, Sohn TA, Yeo CJ, Kern SE, Hruban RH.

Am J Pathol. 2000 Jan;156(1):37-43.

50.

Pathologic examination accurately predicts prognosis in mucinous cystic neoplasms of the pancreas.

Wilentz RE, Albores-Saavedra J, Zahurak M, Talamini MA, Yeo CJ, Cameron JL, Hruban RH.

Am J Surg Pathol. 1999 Nov;23(11):1320-7.

PMID:
10555000

Supplemental Content

Loading ...
Support Center